Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This source highlights that alopecia areata is a complex autoimmune disorder leading to patchy, nonscarring hair loss with variable treatment responses, reflecting unmet clinical needs. Advances in genetic research are improving understanding, yet current treatments often lead to persistent relapses.

This case report describes persistent depigmented hair regrowth from an alopecia areata patch, challenging the previous assumption that such regrowth is only temporary.

This study found that psychological stress significantly influences the onset and severity of alopecia areata, with atopic individuals more likely to develop severe forms like ophiasis.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This study found no association between serum zinc levels and alopecia areata severity in patients.

This study found that drug-induced alopecia areata was most commonly associated with TNF-alpha inhibitors and dupilumab, with most cases improving after discontinuing the medication.

This review discusses the possible link between cosmeceuticals and frontal fibrosing alopecia but reports no conclusive findings; the authors stress further research on environmental triggers is needed.

In this case series, the researchers reported successful individualized homeopathic treatment for alopecia areata in three patients, with each case receiving a specific remedy—Natrum Muriaticum, Calcarea Carbonica, or Argentum Nitricum—resulting in positive treatment outcomes.

This meta-analysis found that patients with alopecia areata, particularly those with more extensive forms like alopecia totalis and universalis, may face a higher risk of cardiovascular disease, though no links were found with specific conditions like ischemic stroke or myocardial infarction.

In this quasi-experimental study, 24-week tofacitinib treatment significantly improved hair regrowth in South Asian patients with alopecia areata, but a high relapse rate post-withdrawal signals the need for continuous treatment strategies.

This review discusses diagnostic challenges and management approaches for pediatric hair disorders, emphasizing the importance of distinguishing between acquired and congenital conditions, and reports no clinical results.

This review examines the clinical presentation of alopecia areata in children and compares it to adult-onset cases, noting that data on pediatric cases is scarce and often varies, with reported onset typically between ages 6 and 12.

This study found that the level of expected therapeutic regrowth significantly affected hair regrowth outcomes in contact immunotherapy for alopecia areata, suggesting implications for patient education and adherence.

In this case report, a 44-year-old man with alopecia areata and seborrheic dermatitis experienced hair regrowth and reduced symptoms after treatment with intralesional corticosteroids, a combination cream, and loratadine, showing improvement within four weeks.

This case report documents the youngest recorded instance of a linear variant of alopecia areata in a 4-year-old child, highlighting the uniqueness and rarity of this clinical presentation and noting its possible association with favorable prognosis, though further evidence is needed.

This study reports a unique case of identical twins experiencing alopecia areata at the same time, suggesting potential environmental triggers for this polygenic autoimmune condition.

In this prospective study, 15 patients with patchy alopecia areata treated with intralesional methotrexate every two weeks showed a significant improvement in hair regrowth and reduction in lesion severity, with changes linked to decreased tissue levels of TNF-α.

This article discusses a case of patchy alopecia areata that spares greying hairs but reports no new findings; it refers to existing literature for context.

This case report describes a 21-year-old man with alopecia areata presenting as a U-shaped hair loss pattern resembling Hamilton grade VII male-pattern baldness, with no signs of inflammation or related conditions.

In this case study, the authors explored the management of ophiasis, a rare and challenging form of alopecia areata, in a 3-year-old boy using the Unani system of medicine, aiming to provide insights for treatment approaches.

This review outlines the mechanisms, clinical features, and management strategies for alopecia areata and presents no new experimental findings.

This article reviews the potential and limitations of cryotherapy for alopecia areata in middle-aged patients and highlights the need for further research, without reporting new clinical findings.

This review compiles existing data on frontal fibrosing alopecia and highlights the promise of 5-alpha reductase inhibitors as a treatment option, while noting the need for clarity on its cause and progression.

This study concluded that combining systemic cyclosporine A with low-dose corticosteroids effectively treats severe alopecia areata while maintaining safe cyclosporine A levels in the blood.

This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.

This study suggests that the rs2075876 variant in the AIRE gene may significantly increase susceptibility to alopecia areata in the examined male population.

In this phase 2 trial, STS01 1% significantly improved hair regrowth in patients with mild to moderate patchy alopecia areata compared to placebo, with a manageable skin irritation side effect profile.

This study found that intralesional corticosteroids remain the preferred treatment for alopecia areata with limited involvement, while platelet-rich plasma showed promise, particularly in children and extensive cases.

This review concluded that baricitinib and other oral JAK inhibitors have the most robust evidence supporting their use in treating severe alopecia areata in adults, compared to other less-evaluated treatments.

This study demonstrated that intramuscular corticosteroids were effective for severe alopecia areata, with significant hair regrowth in 80.2% of patients, though a high relapse rate was noted post-treatment. Nail involvement and disease duration over six months negatively impacted outcomes.